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Abstract 
Background:  Most people with bipolar disorder (BD) spend a significant percentage of their lifetime 
experiencing either sub-syndromal depressive symptoms or full-blown depressive episodes, which 
contribute greatly to the high levels of disability and mortality associated with the disorder. Despite 
the importance of bipolar depression, there are only a small number of recognised treatment options 
available.  Consecutive treatment failures can quickly exhaust these recognised options leading to 
treatment-resistant bipolar depression (TRBD). Remarkably few studies evaluate TRBD and those 
available lack a comprehensive definition of multi-therapy resistant bipolar depression (MTRBD). 
Establishing MTRBD criteria may provide an important signpost to help clinicians consider whether 
people with bipolar depression may benefit from emerging non-standard treatments.    
Aim: To reach consensus regarding threshold definitions criterion for TRBD and MTRBD.  
Method: Based on the evidence of standard treatments available in the latest BD treatment 
guidelines, TRBD and MTRBD criteria were agreed by a representative panel of BD experts using a 
modified Delphi method.  
Results: TRBD criteria in bipolar depression was defined as failure to reach sustained symptomatic 
remission for 8 consecutive weeks after two different treatment trials, at adequate therapeutic doses, 
with at least two recommended monotherapy treatments or at least one monotherapy treatment and 
another combination treatment. MTRBD included the same initial definition as TRBD, with the 
addition of failure of at least one trial with an antidepressant, a psychological treatment and a course 
of electroconvulsive therapy.  
Conclusions: The proposed TRBD and MTRBD criteria may support clinicians, researchers and 
stakeholders in judging how and when to consider new non-standard treatments.  However, some 
challenging diagnostic and therapeutic issues were identified in the consensus process which need 
further evaluation and research.  
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Background 
The treatment of depressive episodes experienced by people with bipolar disorder (BD) is one of the 
most challenging issues faced by both clinicians and researchers. Most people with BD spend a 
significant percentage of their time experiencing either sub-syndromal depressive symptoms or full-
blown depressive episodes and these contribute to the high levels of distress, global disability and 
mortality associated with the disorder 1,2. There are only a small number of licenced therapeutic 
options available for the treatment of bipolar depression, and these often fail to improve patients’ 
symptoms and functionality3. Consecutive treatment failures can rapidly exhaust all recommended 
treatment options. It has been suggested that treatment failure rates might be even higher than in 
major depressive disorder (MDD)4. Despite this, there are remarkably few studies which have 
specifically evaluated treatment-resistant bipolar depression (TRBD) and those available lack a 
common definition of TRBD which makes it difficult to generalize their results 3,5. Fortunately, during 
the last decade, new promising non-standard treatment options have become available, but they are 
either not currently included in guidelines or are only recommended for use by specialist services. 
These emerging treatments have a limited evidence base to support their general use and some are 
associated with significant risks, costs and invasiveness in comparison to standard treatments. More 
importantly, as there is no clear consensus on the criteria defining TRBD, it is difficult to know at which 
point of the treatment pathway these non-standard interventions might be considered. The few TRBD 
definitions proposed so far vary, and most only consider pharmacological options independently of 
more comprehensive and standardized treatments including psychotherapy, physical therapies and 
lifestyle modification 6–8. We have recently published multi-therapy resistance criteria in MDD as a 
guide to when clinicians could consider the use of non-standard treatments9. Adopting a similar 
approach, we first set out to reach a consensus for criteria defining TRBD based on the National 
Institute for Health and Care Excellence (NICE), the British Association for Psychopharmacology (BAP), 
and Canadian Network for Mood and Anxiety Treatments/International Society for Bipolar Disorders 
(CANMAT/ISBD) BD treatment guidelines 10,11. The ultimate and main aim of this study was to reach 
an agreement about the concept and definition of Multi-therapy resistant bipolar depression 
(MTRBD), encompassing pharmacological treatments as well as psychological and physical treatments 
supported by NICE,  BAP, and CANMAT/ISBD treatment guidelines. The purpose of developing MTRBD 
criteria was to define a point in the bipolar depression treatment pathway when clinicians could 
consider the use of non-standard treatments.  
Method 
The development of the criteria definitions followed five successive phases (Figure 1).  Initially, 
representative BD experts from different care levels across the United Kingdom were invited to 
participate. All the contacted experts accepted the invitation. The initial consensus panel was 
composed of 18 BD experts from primary, secondary and tertiary care. Two members of the panel 
(AHY, PRAS) and a facilitator (DHM) developed a first set of TRBD and MTRBD criteria based on the 
latest NICE and BAP treatment guidelines for BD 10,11. These criteria were reviewed and discussed 
during an initial face-to-face and online meeting sponsored by the Royal College of Psychiatrists 
(London, March 2018), and challenging issues highlighted were noted while drawing up the initial draft 
criteria. The meeting participants decided that both TRBD and MTRBD criteria were needed to cover 
the whole trajectory and range of possibilities in the course of treating bipolar depression. To ensure 
that the criteria were as consistent and practical as possible, it was agreed that TRBD criteria should 
be embedded as the initial pharmacological treatment stage of the more comprehensive MTRBD 
criteria as a natural continuum of clinical practice.  
Feedback and discussion from the initial meeting was incorporated into a new second version of the 
draft criteria. This, and unresolved diagnostic and therapeutic issues, were then rated for their 
relevance to be included in the criteria and this manuscript through a modified Delphi method 12,13. To 
ensure criteria generalizability, during the Delphi process, seven non-UK BD experts from key 
representative international societies (Canadian Network for Mood and Anxiety Treatments 
(CANMAT), The International College of Neuropsychopharmacology (CINP), European College of 
Neuropsychopharmacology (ECNP), International Society for Affective Disorders (ISAD), International 
Society for Bipolar Disorders (ISBD), World Federation of the Societies of Biological Psychiatry (WFSBP) 
and the Royal Australian and New Zealand College of Psychiatrists (RANZCP)) were invited to 
contribute along with an expert patient. All the international representatives and the expert patient 
contacted accepted the invitation to be involved in the process.  
[Figure 1 goes here] 
The modified Delphi method was conducted using an online survey collecting anonymous responses 
in three rounds. The items included in the surveys were organized in three sections: (1) statements 
about unresolved elements of the second draft TRBD and (2) MTRBD criteria as well as (3) statements 
about challenging diagnostic and treatment issues identified throughout the process. The participants 
rated the surveys items ranging from “Essential”, “Important”, “Don’t know/Depends”, to 
“Unimportant” or “Should not be included.”  The first survey round also allowed participants to add 
comments and suggestions after rating each item. After reading and analysing the comments provided 
by the participants, three of the authors (AHY, PRAS, DHM), determined if they contained new 
information which merited the addition of a new item in subsequent Delphi rounds. Survey items were 
classified as endorsed, re-rated or rejected. Endorsement cut-off was set to at least 80% of answers 
rating an item as essential or important. Items rated as essential or important by 65% to 79.9% of the 
participants were included in the subsequent rounds for re-rating. These cut-off criteria have been 
also used by similar expert consensus using the Delphi method in the field13,14. Participants could 
decide whether they wanted to maintain or change their previous rating on these re-rated items only 
once; if items did not achieve the threshold for endorsement or re-rate, they were rejected. After each 
round, all the aggregated results were sent to the participants. Items requiring re-rating after the third 
round were mentioned in the results section.   
 
Results 
The initial survey included 33 items (Supplementary material 1) and the second survey included 17 
items of which 3 were items needing re-rating and 14 were new items extracted from the comments 
left by the experts in the first round. All the participants completed the first round of the Delphi survey 
whereas the second and third round were completed by 92.3% (24/26) and 88.5% (23/26) of the panel, 
respectively. In the second round, 7 items were endorsed by the experts, 6 items were excluded and 
4 remained unresolved diagnostic and therapeutic issues which required re-rating. In the final round, 
3 out of the 4 items were endorsed while 1 item remained unresolved.  In total, 15 out of the original 
33 items were endorsed and included in the final criteria (Figure 2).  
[Figure 2 goes here] 
The final consensus reached on the criteria for TRBD and MTRBD are detailed in Table 1 and Table 2.  
[Table 1 goes here] 
[Table 2 goes here] 
TRBD criteria 
The agreed TRBD criteria includes failure to reach sustained remission or tolerate at least two different 
adequate  (at least 8 weeks at therapeutic doses with adequate adherence) treatment trials of 
monotherapy (Quetiapine, Lurasidone, Lamotrigine) or Olanzapine/Fluoxetine combination, or at 
least one of these medications and one of these in combination with Lamotrigine, Valproate or 
Lithium. These criteria were based on NICE, BAP and CANMAT/ISBD bipolar depression guidelines. The 
number of required failed trials was a matter of discussion which required a Delphi round to reach 
agreement. There were concerns that only two trials were a low threshold to consider further 
treatments, whilst on the other hand increasing the number of required treatment trials would extend 
the time that the patient remains symptomatic and inhibit access to other potential beneficial 
treatments. Treatment refractoriness was set as intolerance to treatment or failure to reach 
symptomatic sustained remission after at least eight consecutive weeks with each trial15. For 
Lamotrigine monotherapy, this should be considered as eight consecutive weeks at a stable 
therapeutic dose after initial dose titration. The possibility of patient´s refusal for at least one of the 
trials was considered in the Delphi process, but was ultimately rejected due to the very low threshold 
for the definition and operational uncertainty of standardizing valid reasons for refusal. Other aspects 
confirmed by the first Delphi round included the minimum dose of Quetiapine and minimum lithium 
plasma levels. In both cases, the panel endorsed the minimum effective dose of 300mg/day for 
Quetiapine and plasma levels of 0.8 mEQ/L for Lithium. In the second round, despite some debate 
around the issue, the panel decided to keep Olanzapine-Fluoxetine (OFC), as a treatment option, 
rather than a more generic second generation antipsychotic and antidepressant combination, which 
takes into account that it is a licensed combination (in the USA) for this indication. Although only OFC 
is included in our criteria, we have no reason to believe that other second generation antipsychotic 
and SSRI combinations would not be effective for the treatment of bipolar depression but that this 
hasn't yet been examined in clinical trials. These points are also consistent with other recent 
international BD treatment guidelines16. An additional point which was endorsed by the panel was the 
safety and inefficacy warning about Lamotrigine and Valproate combination. This combination is not 
supported by the guidelines and, if considered, plasma levels and side effects should be closely 
monitored.  
There were some suggestions for adding other agents among the initial pharmacological options 
which, after reviewing the body of evidence provided by the treatment guidelines adopted for this 
study10,11, as well as experts opinions during the Delphi process, were ultimately rejected. They are 
listed in Supplementary Table 1. Finally, the panel agreed that these criteria should apply either to 
working age or older adults diagnosed with bipolar I or II disorder.  
 MTRBD criteria 
The MTBD criteria extends the TRBD criteria by specifying: a trial of Bupropion, or a Selective Serotonin 
reuptake inhibitor (SSRIs) or Serotonin–norepinephrine reuptake inhibitor (SNRIs) for at least 8 weeks 
at therapeutic doses in combination with an anti-manic drug in bipolar I patients and carefully 
monitored in bipolar II patients; a course of cognitive behavioural therapy (CBT); and a trial of electro-
convulsive therapy (ECT) (except in the case of contraindications, intolerance or patient refusal). The 
main points of controversy during the initial discussion and the Delphi process were the types of 
antidepressants and psychological treatments to include in the MTRBD criteria.  
Even though some evidence and prior consensus statements about the use of antidepressant 
monotherapy for bipolar depression discouraged its use, antidepressants are still widely used for the 
treatment of bipolar depression worldwide14,17. It has been also suggested that the risk of switch to 
mania should be balanced and considered on a case-by-case basis rather than imposing a broad 
restriction, especially in the particular circumstances of TRBD in which options are limited18. In this 
context, it was initially proposed that antidepressants should be avoided in those cases with either a 
previous history of rapid cycling, mixed episodes or manic/hypomanic switches or current mixed 
symptoms and agitation. However, the panel did not endorse this as a general rule, but the evidence 
available in guidelines and several comments of the panel emphasised that special care should be 
taken when antidepressants are used for the treatment of bipolar depression10,11. In line with this, the 
panel agreed that if antidepressants are prescribed in bipolar type I depression, they should be used 
adjunctively with an antimanic drug, whereas in bipolar type II depression, monotherapy with 
antidepressants is acceptable but patients should be warned about risk of switch to hypomanic 
symptoms (Bond D, Noronha M, Lam RW, Yatham LN:  Antidepressant-Associated Mood 
Elevations in Bipolar II Disorder Compared With Bipolar I Disorder and Major Depressive 
Disorder: A Systematic Review and Meta-Analysis, Journal of Clinical Psychiatry, 69(10), 1589-
1601,2008)  and they should be careful monitored for emergence of such  symptoms . Recent 
blinded-controlled data comparing SSRI antidepressant versus lithium versus the combination in BDII 
depression found no advantage for lithium and no difference between treatment arms for risk of 
hypomanic switch (Altshuler et al., 2017). The other area where consensus proved harder concerned 
which classes of antidepressants should be considered for the treatment of bipolar depression. The 
general agreement among panel members was to be as pragmatic as possible and not to limit the 
already few options available while balancing the benefit and risks. As a result, SSRIs, SNRIs and 
Bupropion were endorsed by the panel in the final Delphi round.     
The other widely debated area for the MTRBD criteria was the inclusion of psychological interventions 
in the treatment process. This is mainly due to the limited evidence on which guidelines recommend 
these interventions for bipolar depression19. The panel agreed that psychological treatments, in 
general, should be included in the criteria, but due to the lack of evidence of efficacy for bipolar 
depression, only Cognitive Behavioural Therapy (CBT) was endorsed in the last round as a potentially 
useful approach, in particular its behavioural activation component. The inclusion of a structured 
psychoeducation program among the psychological treatments was the only unresolved item not 
reaching endorsement nor rejection rates after the three rounds in the Delphi process. Although the 
effectiveness of a psychoeducational intervention to prevent relapses has been extensively 
demonstrated, the evidence is not robust enough for the treatment of acute episodes20.  Nonetheless, 
and depending on the functional and cognitive status of each individual patient who hasn’t received 
this intervention previously, general or brief psychoeducational interventions might be considered as 
an option, especially taking into account the long time required to complete the whole treatment 
trajectory proposed in MTRBD criteria and long-term relapse prevention after the episode has been 
resolved.   
Finally, at least twelve bilateral sessions of ECT was the last therapeutic option included in the MTRBD 
criteria, provided there were no contraindications and it was accepted and tolerated by the patient. 
Otherwise, it was agreed during the panel discussions, that this should be considered a failed trial, and 
thus, the criteria for MTRBD would have been fulfilled.  
During the panel discussions a number of diagnostic and therapeutic considerations emerged, which 
are outlined below. 
Diagnostic considerations 
Although most treatment guidelines provide recommendations for the management of bipolar 
depression, they provide less clarity about how to address treatment resistance. In reflecting on this, 
the panel provided some theoretical and practical considerations which could be drawn from standard 
clinical practice and guidelines.  
The first of these is the need to ensure that in people with TRBD or MTRBD, a comprehensive medical 
evaluation is required. It is important that clinicians exclude primary organic or pharmacologic causes 
for a depressive episode in BD. This should include a medical screening comprising a complete physical 
examination, blood screening and imaging tests when appropriate. Additionally, any already existing 
organic comorbidities and treatment side-effects should be re-assessed to exclude triggering or 
contributing factors. Abnormal test results  or co-morbid conditions should be evaluated and treated 
by a specialist accordingly21.   
Secondly, given the high prevalence of comorbid psychiatric conditions in BD, the assessment of 
psychiatric comorbidities, particularly substance use, personality and anxiety disorders, is critical in 
the treatment of TRBD and MTRBD as they have been shown to have a negative impact on treatment 
outcomes22–24.  In this context, even if the patient is already well known to the clinician, semi-
structured interviews may be helpful to assist diagnostic co-morbidity assessments25. The co-
occurrence of one or more psychiatric co-morbidities requires a full assessment of its severity and 
specific evidence-based pharmacological and psychological treatments in coordination with 
professionals with expertise in these conditions, if available. Potential depressogenic agents should 
be avoided in the treatment of comorbid conditions, if possible26. However, since co-morbid 
conditions are exclusion criteria in most BD clinical trials, there is little evidence regarding the efficacy 
of commonly used treatments for these patients. 
Finally, the panel considered that it was important to emphasise the need to employ a systematic and 
consistent method to assess the severity of the depressive symptoms, quality of life and functionality 
with standardized scales used throughout the treatment pathway, particularly before and after 
starting new treatments 27. This should include continuous and rigorous medication adherence and 
risk assessment, including for psychotic symptoms and suicidality, as standards of clinical practice10,11.    
Therapeutic considerations 
 
General health and exercise 
Current guidelines recommend a healthy diet, smoking cessation and regular exercise alongside 
pharmacological and non-pharmacological therapies, with appropriate interventions where 
possible10,11,28. Diet, smoking cessation and exercise may benefit physical co-morbidities, the 
metabolic risk factors associated with the use of some pharmacotherapies, and may augment other 
therapies. However, we could not define diet or exercise 'treatment resistance' in TRBD or MTRBD 
because of the limited and heterogeneous evidence base. 
Mixed-states, psychotic and suicidal symptoms 
Even though controversies still exist around the DSM-5 criteria for BD with mixed features, the 
prevalence of mixed features utilizing these criteria has been reported to be as high as one-third of 
bipolar patients suffering a depressive episode29. Hence, we would suggest that screening for mixed 
features should be a priority during the evaluation of depressive symptoms. However, the evidence 
base for the treatment of mixed states is even more limited than for bipolar depression and there are 
no treatments currently approved by the EMA (European Medicines Agency) or FDA (Food and Drug 
Administration) for the treatment of bipolar depression with mixed features. In general terms, 
CANMAT/ISBD, WFSBP, BAP and NICE guidelines discourage the use of antidepressant treatments in 
these circumstances. Second-generation antipsychotics have been specifically evaluated for the 
treatment of depression with mixed features but not all have demonstrated efficacy in bipolar 
depression and most evidence is extrapolated from unipolar depression. Among them, a recent review 
of international guidelines reported that Lurasidone and Ziprasidone plus treatment as usual might be 
useful in acute mixed depression30. ECT might also deserve a special consideration when mixed 
features are present 10.    
Suicide and self-harm 
Following recommendations of existing guidelines and practice standards, the presence of suicidal 
symptoms mandates an ongoing risk evaluation to determine the most appropriate setting to continue 
the treatment. In these cases, a written risk assessment, safety plan and coping strategies must be 
discussed with the patient. Lithium may be effective in preventing suicide in the long-term treatment 
of people with bipolar disorder at increased risk of suicide31. When psychotic or suicidal symptoms are 
present and persistent, a re-evaluation of treatment needs to consider the option of more invasive 
approaches such as ECT 32.    
Special age groups 
The available literature for the treatment for bipolar depression in the perinatal period is generally 
limited, which is reflected in the limited information provided in treatment guidelines. Most of the 
recommendations available come from retrospective reports and/or case studies33,34. However, in 
women of childbearing age with a potential mental health condition, general principles should be 
considered in those fulfilling criteria for TRBD-MTRBD according to existing guidelines available.  In 
this group, we would like to highlight that the use of sodium valproate is contraindicated in females 
of childbearing potential unless conditions of a pregnancy prevention programme are met as is 
detailed in the TRBD-MTRBD criteria35,36.   
The panel agreed in the second round of the consensus process that TRBD-MTRBD criteria should only 
be applied to working age or older adults and should not be applied to children and adolescents. The 
main reason for this decision was that there is insufficient evidence in these age groups about the 
response to standard and non-standard treatments for bipolar depression and sometimes uncertainty 
about the bipolar diagnosis and its potential overlap with the symptoms of other conditions. However, 
NICE guidelines recommend following a similar pharmacological approach as for adults, stressing the 
importance of modifying drug treatments according to age and not routinely continue antipsychotic 
treatment for longer than 12 weeks11. Additionally, these guidelines recommend providing to these 
groups, either an individual CBT or an interpersonal psychotherapy, for at least 3 months. Similarly, 
BAP guidelines recommend following the same pharmacological interventions as in working age adults 
but also considering and balancing dosing and potential harms. Nonetheless, BAP treatment 
guidelines emphasize the scarce empirical evidence available to assume a direct  extrapolation from 
adults’ treatments in these age groups, encouraging an integrated treatment that addresses multiple 
presentations of the illness10. CANMAT/ISBD guidelines recommend that clinical experience combined 
with adult data on bipolar depression and tolerability concerns should guide the clinician in choosing 
the most appropriate options for management of depression in children and adolescents with bipolar 
depression. 
There is also a dearth of studies and evidence-based clinical guidelines in older adults. Due to the 
increased rates of organic comorbidities in this population as well as the reduced hepatic and renal 
clearance, to avoid adverse effects, special caution should be taken titrating and adjusting doses as is 
recommended in existing guidelines10,11,37 Further, CANMAT/ISBD guidelines recommend caution in 
using atypical antipsychotics in older adults given the concerns about side effects. 
Discussion 
In this study, we reached consensus definitions for both treatment resistant bipolar depression and 
multi-therapy resistant bipolar depression. We hope that these criteria will be a useful guide for 
clinicians when they are considering the use of non-standard treatment options and for researchers 
as a framework to guide future studies.  
It is important to note that these are not the first proposed definitions for treatment resistance in 
bipolar depression. Many previous definitions are based on commonalities in the clinical presentation 
and treatment of bipolar depression and major depressive disorder (MDD). Most of these criteria 
include one or two failures to respond to treatments or reach remission to either mood stabilizers 
and/or antidepressants at adequate doses after between 6 and 8 weeks. However, over the last ten 
years, a growing body of evidence has demonstrated marked differences in treatment efficacy of a 
range of treatments, for example SSRI antidepressants, between BD and MDD38 and several studies 
have shown the useful role of Quetiapine, Olanzapine, Cariprazine and Lurasidone for the treatment 
of bipolar depression39.  
In this context, Pacchiarotti et al. previously provided a stepwise series of definitions for treatment 
refractoriness in bipolar depression ranging from treatment-resistant to involutional bipolar. The first 
step of this definition for bipolar type I depression defined treatment resistance as a failure to reach 
remission with adequate plasma levels of lithium (0.8 mEq⁄l) or to other adequate ongoing mood-
stabilizing treatment, plus Lamotrigine (50–200 mg⁄day) or with full dose (≥600 mg⁄day) of Quetiapine 
as monotherapy (300-600 mg ⁄day allowed for bipolar II depression)6. An adequate trial period to 
reach remission was defined as 8 weeks as in our criteria. Our criteria contain similar options to those 
of Pacchiarotti, but more explicitly allow for combination therapy and do not insist on a minimum of 
600mg Quetiapine for bipolar I depression. Since the recommendations of Pacchiarotti, new emerging 
evidence and consensus have been published, especially regarding the use of antidepressants, as well 
as other standard treatments (i.e. Lurasidone)5,14. As a result, guidelines have been updated 
accordingly and these changes have been reflected in our version of the TRBD definition criteria. In 
comparison to previous proposed criteria, our MTRBD criteria were developed with a more pragmatic 
approach but within the evidence framework of the latest NICE, BAP, and CANMAT/ISBD 
guidelines10,11. 
 
Strengths and limitations 
This is the first study in which both TRBD and the new concept of MTRBD criteria were agreed by a 
diverse but highly qualified group of international experts, including a patient expert, using a 
systematic Delphi consensus process. Our TRBD and MTRBD criteria are also based on the most 
updated and highest quality BD treatment guidelines (NICE, BAP and CANMAT/ISBD). As a result, the 
criteria are well supported by standardized guidelines evidence and are highly applicable to real-world 
clinical practice. However, for the same reasons, the criteria may be affected by the limitations and 
biases of the evidence contained within current guidelines. This also limits the generalization of these 
criteria to other regions of the world where treatments included in the criteria might not be available.  
Currently, there is very limited evidence to guide the management of TRBD. The evidence that does 
exist comes from remarkably few randomised controlled trials and also open studies, case series and 
reports. Furthermore, the lack of a common TRBD definition used in this research limits the 
generalizability of their results. This is potentially one reason why treatment assumptions based on 
data extrapolated from the treatment of unipolar depressive episodes continue to exist3,5,8.    
There are some obvious limitations inherent to the Delphi method and how we implemented it. First, 
the initial set of TRBD and MTRBD criteria were previously developed and discussed in a panel of 
experts comprising three-quarters of the whole final Delphi participants, leaving the remaining 
members of the panel with fewer possibilities to modify the initial criteria or raise further points. 
However, the first round of the Delphi survey included the possibility to add further comments to each 
item to be considered during subsequent rounds. Secondly, there is also a potential lack of 
heterogeneity in an expert panel from a specific field which could lead to shared bias in the area. To 
balance for this, the initial panel was not limited to secondary and tertiary care participants but also 
included a primary care expert. Additionally, to minimize regional biases and increase the chances of 
generalizability, the participation in the process of international representatives from leading 
professional societies and an expert patient could be considered as a strength of this study to 
overcome the above-mentioned issues.  
Finally, it is important to emphasise that the proposed TRBD and MTRBD criteria does not imply 
treatment recommendations that clinicians should follow for therapeutic refractoriness in BD. The 
rationale for our suggested criteria is to help clinicians, researchers and other stakeholders in 
determining when non-standard treatment options could be considered. An overview of the current 
non-standard treatments available for MDD, which might also be extrapolated to bipolar depression, 
is available in our recently published work about the definition of multiple-therapy-resistant MDD9.  
 
Conclusion 
The criteria reached in this consensus should be considered as a complement to clinical expertise as 
well as the resources available and the particular clinical characteristics and preferences of every 
single person suffering from bipolar depression. We hope these criteria will guide clinicians, 
researchers and stakeholders on the most appropriate point of the bipolar depression treatment 
pathway to consider the use of non-standard treatments. Among the unresolved diagnostic and 
therapeutic issues, the utility of different antidepressants classes and psychological interventions for 
the treatment of bipolar depression remain as pressing questions urgently needing further research.  
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